By Jeffrey Dvorin
The vast majority of biotechnology companies today have abandoned the traditional discovery model—determining that it's simply too expensive and time-consuming...
Cytokinetics Stays the Course
Cytokinetics claims to have implemented a far more detailed long-term strategic plan than most biotechs. That plan will be put to the test as it enters the clinic with an acute CHF compound. Until now, the company has relied on a partner (GSK) to shoulder the burden of developing its drug candidates. Now it will have to do that heavy lifting, at least for a while, on its own.